id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-253285-kskuz1ug	Hage, René	444Calcineurin Inhibitors and COVID-19	2020-09-24		.txt	text/plain	190	22	46	key: cord-253285-kskuz1ug title: 444Calcineurin Inhibitors and COVID-19 cord_uid: kskuz1ug Secondly, the inhibiting effect of CNIs on viral replication of other coronaviruses has been demonstrated in some studies. In vitro studies showed effectiveness of CsA in some coronaviruses 5, 6 . Tacrolimus has been suggested to be effective for disease caused by the MERS-CoV 7 . Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia Biologic Therapy in COVID-19. Calcineurin inhibitors revisited: A new paradigm for COVID-19? The Brazilian Journal of Infectious Diseases COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review Suppression of coronavirus replication by cyclophilin inhibitors Cyclosporin A inhibits the replication of diverse coronaviruses Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury (TACROVID)	./cache/cord-253285-kskuz1ug.txt	./txt/cord-253285-kskuz1ug.txt